NSAV Announces Major Reduction of Authorized Shares

New Post Public Reply Private Reply Replies (0) Message Board
wayno2
73
NSAV Announces Major Reduction of Authorized Shares

CRESCO, PA -- (Marketwired) -- 03/21/17 -- Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a major reduction of its authorized shares. The exact amount of the decrease will finalized in the coming days and will be publicly disclosed in a comprehensive press release within a week. The Company will be consulting with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The current management of NSAV had planned a major reduction of its authorized shares, which was increased by the former management in July 2015. The Company decided to take this action and make this announcement earlier than planned in response to numerous shareholder inquiries, in which the NSAV shareholders were afraid of an immediate and substantial dilution of it shares. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place.

Further, the Company believes the issued and outstanding share count of 3,149,504,075 is accurate and has today requested that the transfer agent confirm this amount. Once the Company receives confirmation from the transfer agent, it will immediately post the number on its OTC Markets corporate profile page.

The Company also announced a reaffirmation of its previously released public statement, that it is categorically not planning or even considering a reverse split of its shares. This is in response to continued shareholder fears of an imminent reverse split.

James Tilton, president of NSAV stated, "It is with great pleasure that I can confirm that the Company will enact a drastic reduction of its authorized shares. I can assure all of our shareholders that this action will benefit them. As I have stated on numerous occasions, I am fully committed to only taking action that are in the best interest of all NSAV shareholders. I also want to reaffirm that I do not own a single share of NSAV common stock or any security that converts into even one share of common stock."

Mr. Tilton went on to state, "Once again I can confirm that neither myself, nor any other person associated with the company, had any knowledge that the transfer agent issued 149,666,667 new shares until the transfer agent confirmed it to me personally a week after the shares were issued. This fact is evidenced by numerous emails that I have sent to the transfer agent, which several shareholders have posted on the internet. I urge all shareholders to refrain from focusing on this share issuance, albeit a serious matter and allow the Company to get back to work making acquisitions and bringing its SEC filings up to date. These are the critical issues at hand for the Company at the present time."

Mr. Tilton further went on to state, "I also sincerely hope that we have put the issue of a reverse split to bed once and for all. We will grow NSAV from the ground up, by making timely and solid acquisitions that will greatly enhance shareholder value. A reverse split never enhances shareholder value and I personally haven't been involved with a company that enacted a reverse split in fifteen years."

NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, financial services, patents and trademarks and information technology.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.

For further information please contact:
NSAV
1 (570-595-2432)
jamestilton@netsavingslinkinc.com

Source: Net Savings Link, Inc.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 92

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 88

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Updated Category News Views 82

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Continue Reading
James Hardie Joins S&P MidCap 400; Roku Acquired

Updated Category News Views 80

A Shift in the MidCap 400: What's Up? Well, wouldn’t you know it, James Hardie Industries is making waves as it steps into the S&P MidCap 400. This move happens because Fox Corp. has nabbed Roku in a deal worthy of some popcorn. Come November 11, when the trading floor wakes up, James Hardie will be in and Roku will be out. Pretty neat switcheroo if you ask me. Inside...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 100

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 163

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
IRTC Faces Investigation: Shares Plunge Amid Uncertainty

Updated Category News Views 63

Securities Trouble on the Horizon: IRTC Takes a Hit Wake up and adjust your seat, folks—iRhythm Technologies (NASDAQ:IRTC) is in the spotlight, and it ain't pretty. Shares nosedived over 30% in a single morning, stirring up quite the murky waters for shareholders. The trigger? A less-than-stellar third-quarter report. The Numbers Don't Lie—Or Do They? Management...

Continue Reading

Top 5 Most Recently Viewed Articles

Apertura Gene Therapy Collaborates on Prion Disease Treatment

Updated Category News Views 123

Apertura Gene Therapy Teams Up with Broad Institute Apertura Gene Therapy, a leading biotechnology firm committed to pioneering solutions in gene therapy, is collaborating with the Broad Institute, which is renowned for its groundbreaking research initiatives. The project aims to advance the development of a novel gene therapy targeting prion disease using an engineered...

Continue Reading
Bausch & Lomb Exceeds Expectations with Strong Q3 Growth

Updated Category News Views 67

Bausch & Lomb Achieves Impressive Third Quarter Results Bausch & Lomb Corp. (NYSE:BLCO) has recently captured attention in the financial markets after delivering strong third-quarter results for 2024. H.C. Wainwright, a prominent investment firm, revised the stock price target upward to $23.00 from the previous $22.00 while maintaining a Buy rating on the stock. This...

Continue Reading
Experience Winter Delights with BIGGBY® COFFEE's TWIX® Treats

Updated Category News Views 141

Discover the Seasonal Magic of BIGGBY® COFFEE The new limited-time winter offerings from BIGGBY® COFFEE are designed to delight cocoa and coffee lovers alike. This season, fans can indulge in a unique Salted Caramel lineup inspired by TWIX® candy. These festive beverages are available from early January through late February, providing a decadent way to enjoy the...

Continue Reading
Borr Drilling Limited's New Offering: What Investors Should Know

Updated Category News Views 229

Borr Drilling Limited Plans Significant Share Offering Borr Drilling Limited (NYSE: BORR) has recently announced plans to conduct a public offering of its common shares, intending to raise approximately $85 million in gross proceeds. The company aims to offer around 21 million shares in this equity initiative, reflecting its commitment to continued growth and investment...

Continue Reading